- /
- Supported exchanges
- / US
- / DSKYF.PINK
Daiichi Sankyo Company Limited (DSKYF PINK) stock market data APIs
Daiichi Sankyo Company Limited Financial Data Overview
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Daiichi Sankyo Company Limited data using free add-ons & libraries
Get Daiichi Sankyo Company Limited Fundamental Data
Daiichi Sankyo Company Limited Fundamental data includes:
- Net Revenue: 2 314 925 M
- EBITDA: 375 224 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Daiichi Sankyo Company Limited Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-07-31
- EPS/Forecast: 36.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Daiichi Sankyo Company Limited News
New
Antibody-Drug Conjugates (ADC) Market Size, Share, Trends, and Global Forecast to 2036 | Market Set to Reach $74.15 Billion at 13.5% CAGR as Next-Generation ADCs and Asia-Pacific Drive Growth
Company Logo Dublin, Nov. 05, 2026 (GLOBE NEWSWIRE) -- "Antibody-Drug Conjugates (ADC) Market Size, Share, and Industry Analysis - Global Forecast to 2036" has been added to ResearchAndMarkets.com's ...
Enhertu® Wins 2026 International Prix Galien Award for Best Biotechnology Product
Second Prix Galien Award for Daiichi Sankyo and AstraZeneca's Enhertu following receipt of the Prix Galien USA Award in 2024 TOKYO, October 30, 2026--(BUSINESS WIRE)--Enhertu® (trastuzumab deruxteca...
Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up
Investing.com-- Daiichi Sankyo (TYO:4568) reported stronger earnings for the first half of its fiscal year, supported by robust demand for its cancer treatments and a weaker yen, as the Japanese drugm...
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
Revenue increased 19.7% to 1.167 trillion yen year-over-year driven by Enhertu® and Datroway® Fiscal year 2026 guidance for revenue and operating profit remains unchanged Earnings call to take place...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.